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Reduced-intensity conditioning (RIC) regimens have the potential to decrease toxicities related to hemato-
poietic stem cell transplantation (HCT) in patients with sickle cell disease (SCD) and thus make HCTa more
acceptable therapeutic option for this group of patients. We report the results of 7 patients enrolled on
a study to evaluate safety and efficacy of HCTusing bone marrow from an HLA matched sibling donor fol-
lowing an RIC regimen for patients with high-risk SCD. The conditioning regimen consisted of busulfan, flu-
darabine, equine antithymocyte globulin, and total lymphoid irradiation with shielding of the liver, lungs,
heart, and gonads on day 1. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and
mycophenolate mofetil. The regimen was well tolerated, and all patients had hematopoietic recovery. Six
of 7 patients are stably engrafted off immunosuppression and without sickle cell-related symptoms at 2 to
8.5 years after HCT. Consistent with the complete resolution of SCD related symptoms observed in the
6 engrafted patients, erythropoiesis of complete or predominantly donor origin was detected by red blood
cell-specific chimerism assays, despite their having persistent mixed chimerism in the mononuclear and lym-
phoid compartments. These findings demonstrate the curative potential of allogeneic HCTafter an RIC reg-
imen in patients with SCD.
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Despite the advances in the health care of children
with sickle cell disease (SCD) over the last 30 years,
this disease continues to be associated with consider-
able morbidity and premature mortality, with a 25-
to 30-year loss of life expectancy [1,2]. Stroke, organ
failure, acute chest syndrome, pulmonary hyperten-
sion, and recurrent pain crises cause significant mor-
bidity. Transfusion therapy decreases recurrence of
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1270stroke and other complications, but at the expense of
increased risk for transfusion reactions, infections,
and iron overload [3]. Hydroxyurea increases the total
hemoglobin concentration, reduces the vaso-occlusive
complications of pain and acute chest syndrome, and
attenuates mortality in adults [4]. However,\30% of
eligible patients are either prescribed or take this
drug; not all adults respond to this treatment, and
a small and as yet unquantified risk of latent transfor-
mation to leukemia with its long-term use remains as
a concern [5].
Currently, allogeneic HCT is the only curative
therapy for SCD. The results of HCT after conven-
tional myeloablative therapy in young patients
(\16 years of age) with SCD are highly encouraging,
with an overall event-free survival (EFS) of approxi-
mately 85% and transplant-related mortality of
\10% [6-13]. Moreover, stabilization or reversal of
organ damage from SCD has been documented after
HCT [14]. Despite these encouraging results, the use
of this treatment approach has been limited by the in-
frequent availability of an HLAmatched sibling donor
[15] and the risks of early and late regimen-related
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Pt #
Age
(Years/Sex)
Recipient
b - Globin
Genotype and
Indication
for HCT
Donor b -Globin
Genotype
Conditioning
Regimen
Donor ABO
Compatibility
Infused Marrow
Product
(Cell Dose/kg Body Weight)
Number of Transfusions
post HCT
(Day of Last Transfusion)
TNC
(108)
CD34
(106)
CD3-
(107)
Duration of
ANC<0.5
109/L (Days) PRBC Platelets
1 8/F b s b s Stroke,
Allosensitization
b b s BU, Flu,
ATG, TLI*
matched 3.49 6.25 0.5 8 3 (100) 3 (22)
2 8/M b s b s Repeated ACS b b BU, Flu,
ATG, TLI*
matched 5 1.26 0.5 8 3 (20) 3 (28)
3 6/M b s b s Repeated ACS,
Silent stroke
b b s BU, Flu,
ATG, TLI†
matched 4.51 3.49 0.5 14 3 (35) 3 (11)
4 8/M b s b 0 Repeated ACS b b 0 BU, Flu,
ATG, TLI†
major
mismatch
4.3 4.72 0.54 13 3 (35) 3 (18)
5 18/F b s b s Stroke,
Thrombosis,
Allosensitization
b b s BU, Flu,
ATG, TLI†
matched 2.61 1.02 0.28 13 3 (39) 3 (16)
6 16/M b s b s Repeated ACS
AVN,
Recurrent
pain crises
b b s BU, Flu,
ATG, TLI†
matched 4.25 3.7 0.55 13 1 (35) 4 (15)
7 16/F b s b s Repeated ACS b b BU, Flu,
ATG, TLI†
matched 3.20 1.35 0.20 17 6 (35) 14 (25)
HCT indicates hematopoietic stem cell transplantation; ANC, absolute neutrophil count; TNC, total nucleated cells; PRBC, packed red blood cell;
ATG, amtithymocyte globulin; BU, busulfan; TLI, total lymphoid irridiation; FLU, fludarabine.
*Busulfan was administered orally.
†Busulfan was administered intravenously.toxicities related to intensive myeloablative therapy,
especially in patients .16 years of age. These risks in-
clude organ toxicities, acute and chronic graft-versus-
host disease (aGVHD, cGVHD), and late effects,
including sterility and secondary malignancies. There-
fore, as a means to reduce both acute and long-term
toxicities, we evaluated the safety and efficacy of a re-
duced-intensity conditioning (RIC) approach for
SCD.
MATERIALS AND METHODS
Study Subjects, and Patient Samples
Pediatric and adult patients with SCD with severe
phenotype and without end-organ failure were consid-
ered eligible for this study, using the criteria previously
described in a national collaborative trial for myeloa-
blative HCT for SCD [13]. The study protocol was
approved by the institutional review boards of theUni-
versity of Pittsburgh, University of Minnesota and
University of Alabama, Birmingham. All subjects or
their legal guardians provided signed informed
consent.
Conditioning and GVHD Prophylaxis Regimens
Preparative regimen
Patients were conditioned for transplantation with
a regimen consisting of busulfan (BU) 0.8 mg/kg/dose
intravenously every 6 hours, or 4 mg/kg/day orally in 2divided doses on days 28 and 27, with targeted dos-
ing, to achieve a BU steady state of 600-900 ng/mL;
fludarabine (FLU) 35 mg/m2 i.v. daily on days 26,
25, 24, 23, and 22; and equine antithymocyte glob-
ulin (ATG) 30 mg/kg i.v. daily on days 25, 24, 23,
22, and21. Total lymphoid irradiation (TLI) was ad-
ministered on day 22 as a single fraction of 500 cGy,
with shielding of the liver, lungs, heart, and gonads.
As patients were accrued over a 9-year period, a num-
ber of adjustments to the conditioning regimen were
implemented over time, reflecting changes in clinical
practice [16-18]. As shown in Table 1, the primary
change was conversion of busulfan from an oral (pa-
tients 1-2) to an intravenous (patients 3-7) formula-
tion.
GVHD prophylaxis
Posttransplantation immunosuppression consisted
of cyclosporine and mycophenolate mofetil (MMF).
Cyclosponine (CSA) was initiated on day 23 at 2.5
mg/kg i.v. over 2 hours every 12 hours for adults
with normal renal function. For children\40 kg, the
initial dose was 2.5 mg/kg i.v. over 2 hours every 8
hours. CSA was continued until day 180, and dose ad-
justments were made on the basis of toxicity and to
maintain CSA trough levels of 200-300 mg/L. If no
GVHD was observed, the CSA dose was tapered
10% per week beginning on day 181. MMF was initi-
ated on day 0 at 15 mg/kg intravenously or orally twice
a day. Subsequently, theMMF dose wasmodified to 15
mg/kg/dose or 1g thrice daily (whichever was lower)
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doses per day once oral medications could be toler-
ated. MMF was tapered over 8 weeks starting days
145-220.
Supportive care
The conditioning regimen, bone marrow infusion,
and initiation of the GVHD regimen were adminis-
tered in the inpatient setting for all patients. Patients
were discharged to the outpatient setting as soon as
clinically stable. All patients received antimicrobial
prophylaxis consisting of oral acyclovir, penicillin,
and trimethoprim/sulfamethoxazole, and fluconazole
while concurrently on immunosuppression. Blood
samples were tested weekly for at least 12 weeks after
transplantation for evidence of cytomegalovirus reacti-
vation by using a nucleic acid hybridization test (Di-
gene Corp., Gaithersburg, MD) or by testing for
cytomegalovirus (CMV) antigen by shell vial assay.
For patients not on a chronic transfusion protocol
and having a sickle hemoglobin (Hb S) concentration
.30%, a partial exchange transfusion was performed
to reduce the Hb S to 30% or lower prior to initiating
the conditioning regimen. Transfusions of packed red
blood cells (PRBC) were administered as needed to
maintain a total Hb level of 9-11 g/dL through day
100. Prophylactic platelet transfusions were given to
maintain the platelet count.50 109/L. Tominimize
the risk of central nervous system (CNS) toxicity fol-
lowing HCT, prophylactic phenytoin or levetiracetam
was started prior to BU administration and continued
for the duration of CSA therapy, while maintaining se-
rum magnesium levels in the normal range and while
keeping platelet counts .50  109 cells/L [13].
Engraftment and Measurement of Overall
Donor Engraftment and Chimerism
Neutrophil engraftment was defined as the pres-
ence of absolute neutrophil count .0.5  109 cells/L
for 3 consecutive days. Platelet engraftment was de-
fined as platelet count .50  109 cells/L maintained
without platelet transfusions. For all patients, extent
of overall donor engraftment in peripheral blood
mononuclear cell (PBMC) and bone marrow (BM)
was determined by quantitative polymerase chain reac-
tion analysis of informative polymorphic regions of ge-
nomic DNA. Genomic DNAwas extracted from 1 to 3
 106 PBMC or bone marrow mononuclear cells ac-
cording to the manufacturer’s protocol (Wizard kit,
Promega, Madison, WI). For sex mismatched donor-
recipient pairs, overall donor engraftment was also
measured using Y-chromosome specific probes by
fluorescent in situ hybridization analysis.Whole blood
and marrow samples for evaluation of disease and chi-
merism were obtained on days 30, 60, 100, 180, and360 after HCT and at point of last contact prior to
this report.
Measurement of Lineage Specific Donor
Engraftment
Mononuclear cells derived from posttransplant
samples were isolated by Ficoll-Hypaque density gra-
dient centrifugation. CD3-positive cells were isolated
by flow cytometry (Hematologic, Inc., Seattle, WA)
or by immunomagnetic bead selection (Miltenyi, Au-
burn, CA) for T cell chimerism analysis. Erythroid lin-
eage specific chimerism was performed by b-globin
RNA pyrosequencing as previously described [19,20].
Briefly, polymerase chain reaction (PCR) was per-
formed utilizing primers specific for b-globin cDNA
(reverse transcribed from RNA), such that the ampli-
con encompassed the sickle mutation on the b-globin
locus. Quantitation of patient versus donor b-globin
transcripts was performed by pyrosequencing, in
which biotinylated single-strand DNA fragments
were generated bymixing the PCR product with strep-
tavidin-coated paramagnetic beads (Dynalbeads
M280; Dynal, Norway) and processed according to
the manufacturer’s instructions on an automated pyro-
sequencing instrument, PSQ96 (Pyrosequencing AB,
Uppsala, Sweden). Erythroid-lineage specific chime-
rism was quantified using Pyrosequencing software
(Pyrosequencing AB).
Assessment of Organ Function and Recovery
All patients continue to be regularly followed by
their primary hematologist and transplant physician
with physical examination, blood counts, blood urea
nitrogen, and creatinine and liver function tests.
They undergo screening with transcranial Doppler ul-
trasound (TCD) annually. In the case of prior stroke,
follow-up head magnetic resonance imaging (MRI)
studies have been obtained yearly for 3 years after
HCT and then as clinically indicated. Electrocardio-
gram, echocardiogram, and pulmonary function tests
were obtained annually for 3 years post-HCT and as
indicated thereafter.
RESULTS
Patient Characteristics
Seven patients with severe SCD underwent HCT.
All patients or their parents were also offered myeloa-
blative HCT, but this treatment option was refused.
The early clinical results of Patient 1 has been previ-
ously reported [21]. The median age of the patients
was 8 years (range: 6-18 years). Three of 7 patients un-
derwent transplant for silent or clinical stroke, whereas
4 of 7 had a history of recurrent acute chest syndrome
(Table 1). Patient 5 is a young adult whose prior clinical
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Pt #
Follow-up
(Years)
Regimen-Related
Toxicity
(Days Post-HCT)
Weaning of Immunosuppression
(Days Post-HCT When Initiated) End-organ Recovery (Pre- versus 1-Year Post-HCT)
Infections
(Days Post-HCT) MMF CSA
GVHD
(Acute/Chronic)
Head
MRI
Pulmonary
Status*
Creatinine
(mg/dL)
Splenic
Fnnction†
Cardiac
Status‡
1 8.5 Nil Line-related
bacteremia
(d100)
45 180 None/None Stable Stable 0.5/0.6 No/Yes Stable
2 8 Seizure (day +11) Nil 45 180 Grade II
skin/None
Stable Stable 0.4/0.5 Prior
splenectomy
Stable
3 5 Headache
(day +1 to +4)
Hemoglobinuria
(day 0)
Nil 220 320 None/None Stable Stable 0.4/0.5 No/Yes Stable
4 3.5 Nil Nil 180 300 None/None Stable Stable 0.6/0.6 No/Yes Stable
5 3.5 Pancreatitis (mild)
(day +109)
Influenza A
and herpes
zoster (d106)
180 220 None/None Stable Stable 0.7/0.7 No/Yes Stable
6 2 Nil Nil 180 300 None/Limited
chronic
GVHD of skin
Stable Stable 0.7/0.7 No/Yes Stable
7 1.5 Nil Line-related
bacteremia
(d244)
100 180 None/None NA NA 0.7/0.6 NA NA
PFT indicates pulmonary function test; NA, not available; MRI, magnetic resonance imaging; HCT, hematopoietic stem cell transplantation.
*Pulmonary status measured by PFTs.
†Splenic recovery measured by spleen scan.
‡Cardiac status measured by EKG and Echo.course was complicated by several severe comorbidities
including sickle cell lung disease, allosensitization, au-
toimmune hemolytic anemia, severe transfusional iron
overload of the liver and transient renal insufficiency re-
lated to iron chelation. As shown in Table 1, all patients
received unmanipulated bone marrow from an HLA-
matched sibling donor, with total nucleated cell number
and CD341 dose ranging from 2.45-5.0  108 cells/kg
and 1.2-12.0  106 cells/kg, respectively. The median
follow-up was 4 years (range: 2-8.5 years).
Immediate Posttransplant Toxicity and
Hematologic Recovery
The preparative regimen was very well tolerated,
and immediate treatment-associated complications in
all 7 patients were mild and reversible. These are sum-
marized in Table 2. None of the patients developed
mucositis. Patient 3 required analgesics for intense
headaches that were attributed to MMF. Two patients
required transient parenteral alimentation because of
poor oral intake. Patient 2 experienced a single gener-
alized seizure associated with subtherapeutic levels of
phenytoin. Patient 3 developed hemoglobinuria im-
mediately following stem cell infusion that recovered
within 48 hours. Infectious complications consisted
of coagulase-negative Staphylococcus bacteremia, der-
matomal herpes zoster parainfluenza A infection, and
line-related bacteremia with Rhizobium radiobacter.
The hematologic recovery of all 7 patients within
the first 100 days following RIC HCT was prompt.
As shown in Figure 1A, myelosuppression was limitedto a median nadir absolute neutrophil count of 0.1 
109/L (range: 60-130) and a median nadir platelet
count of 31 109/L (range: 10-40). As shown in Table
1, median duration of neutropenia (absolute neutrophil
count\0.5  109/L) was 13 days (range: 8-17 days).
Normal platelet and neutrophil counts were achieved
by a median of 34 days (range: 27-35), and 22 days
(range: 19-27), respectively. Patients received a median
of 3 (range: 1-6) PRBC transfusions and 3 (range: 3-14)
platelet transfusions. The median duration for require-
ment of transfusion of PRBC and/or platelets (Table 1)
was 37 and 17 days, respectively. As shown in
Figure 1B, patients achieved transfusion independence
after a median of 35 days post-HCT. Six of 7 patients
have normal platelet, white and red blood cell (RBC)
counts at 2-8 years follow-up, whereas 1 of 7 initially
engrafted, but subsequently lost the graft at day 244
with complete autologous recovery of hematopoiesis.
Bone marrow examination at day 365 in all engrafted
patients demonstrated normal cytogenetics.
GVHD
Patients 1 and 2 began their taper of MMF on post-
transplant day 45 andofCSAdoses at posttransplant day
180 (Table 2). Subsequently, early partial donor chime-
rismwasobserved inpatients3 and4.Becausemixed chi-
merismmaybe associatedwithgraft rejection [22], in the
ensuingpatients, taperingofMMFandCSAwasdelayed
until days 100-220, and 180-320 days, respectively.
As shown in Table 2, none of the patients devel-
oped greater than grade 2 aGVHD or extensive
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cGVHD (patients 1, 3, 4, and 7). Of the remaining 3,
only 1 (patient 2) developed mild aGVHD, manifested
as stage II skin GVHD, which resolved with predni-
sone therapy. At 6 years follow-up, this patient has
not developed cGVHD. Patient 5 developed bilateral
nongranulomatous uveitis 15 months after HCT
with no other definite evidence of cGVHD that has
been well controlled with topical steroids and weekly
oral methotrexate. Patient 6 developed limited
cGVHD of the skin at day 180 as CSA was being ta-
pered. He was successfully treated with CSA and pred-
nisone started at a dose of 2 mg/kg for 2 weeks, and
then gradually weaned until all immunosuppression
was removed.
Total and Lineage-Specific Chimerism following
RIC HCT
We measured total PBMC chimerism on all 7 pa-
tients at 1 year following HCT, when they were no
longer on immunosuppressive medications. We ob-
served frequent mixed hematopoietic chimerism. As
shown in Figure 2, 6 of 7 patients (patients 1-6) dem-
onstrated high levels of donor engraftment, whereas
patient 7 had already lost donor engraftment at this
Figure 1. Recovery of (A) neutrophils and platelets, and (B) hemoglo-
bin levels during the first 100 days following HCT in patients 1-7. Median
duration of neutropenia (defined as ANC\0.5  109/L) was 13 days
(range: 8-17 days). Median duration thrombocytopenia requiring trans-
fusion (platelet count\50  109/L) was 17 days. Median duration of
days during which platelet and PRBC transfusions were needed are indi-
cated by the shaded gray regions.time point. Of the 6 engrafted patients, 2 demon-
strated full donor chimerism, whereas 4 were partially
engrafted, at levels ranging from 71% to 95%. The 2
patients who demonstrated full mononuclear cell chi-
merism (patients 1 and 5) also demonstrated full T
cell donor chimerism. The 4 patients with partial do-
nor chimerism, however, all demonstrated lower levels
of T cell chimerism at 1 year following HCT, ranging
from 17% to 65%.
We also sought to define the extent to which HCT
corrected these patients’ underlying RBC disorder. As
shown in Figure 1B, patients with stable donor chi-
merism (patients 1-6) demonstrated a median hemo-
globin level of 11.3 g/dL (range: 10.1-13.3). To
determine the extent to which circulating RBCs were
donor derived, we measured peripheral blood ery-
throid precursor chimerism by b-globin pyrosequenc-
ing [20] in 4 of the 6 patients with stable engraftment
forwhom sampleswere available. As shown in Figure 2,
all 4 were measured to have.90% donor RBC chime-
rism. Consistent with these results, all 6 engrafted pa-
tients demonstrated the percentage Hb S in the blood
expected from the donor’s genotype. As shown in
Figure 3, in patients transplanted from a donor with
sickle cell trait, the median percentage Hb S was
33%, whereas those with nonsickle cell trait donors
had undetectable Hb S levels.
To determine the long-term impact of our trans-
plant regimen on engraftment in our patient cohort,
we measured total and lineage specific chimerism in
peripheral blood at the time of last contact (median
of 4 years) after HCT (Figure 4). All 6 patients demon-
strated a median level of donor chimerism of 78% in
the mononuclear compartment, 98.5% (range: 76%-
100%) in the erythroid compartment and 68.5%
(range: 50%-90%) in the peripheral lymphoid com-
partment, 2-8.5 years post-HCT. Compared to 1
year after HCT, levels of donor lymphoid and mono-
nuclear chimerism were stable or rose in 5 of 6
Figure 2. Lineage-specific peripheral blood donor chimerism at 1 year
after HCT. Chimerism was examined in the mononuclear (dark gray
bars), CD31 lymphoid chimerism (light gray), and RBC precursor (black
bars) compartments. *Sample unavailable for analysis.
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chimerism remained .70% donor derived in all 6 pa-
tients. These data demonstrate that long-term stable
donor engraftment in the mononuclear, lymphoid,
and erythroid compartments can be achieved follow-
ing RIC HCT for SCD.
Noncompliance and Delayed Loss of
Engraftment
Overall, 6 of 7 patients were highly compliant with
the posttransplant immunosuppressive regimen. Pa-
tient 7, however, was noncompliant with cyclosporine
after day 120. At day 244, following an episode of cen-
tral venous line-related bacteremia, the patient became
pancytopenic. During this time, peripheral blood
mononuclear chimerism decreased from 90% to 3%
over a period of 2 months and CD31 lymphoid chime-
rism decreased from 11% to 3%. Bone marrow exam-
ination revealed a very hypocellular marrow. She
required platelet and RBC transfusions and intermit-
tent administration of granulocyte-colony stimulating
factor (G-CSF). Since day 330, she has demonstrated
autologous recovery of her bone marrow with normal
platelet counts, and white blood cell count and differ-
ential. Moreover, donor chimerism in the mononu-
clear, erythroid, or lymphoid subsets was not
detectable, and %Hb S in peripheral blood has slowly
risen from 0% without transfusion, at day 240 to 60%
at day 1365.
Survival and End-oOgan Effects of RIC HCT
At a follow-up of 2-8.5 years after transplantation,
all 7 patients are alive. All patients are entirely off im-
munosuppression and 6 of 7 patients have no labora-
tory or clinical evidence of disease. When assessed 1
year after HCT, all 7 patients demonstrated stable
head MRI findings and lung function, as measured
Figure 3. At 1-year post-HCT, transplanted SCD patients with stable
engraftment demonstrate percentage of hemoglobin S (Hb S) in periph-
eral blood of a similar level to their donors. Patients 1, 3, and 5 received
HCT from donors with sickle cell trait, wheres the donors of patients 2,
4, and 6 were normal nonsickle trait (AA) donors.by pulmonary function tests. None of the 7 patients
had measurable pulmonary hypertension prior to
transplant, and all have normal echocardiograms after
transplant. In addition, normal renal function was re-
gained following HCT in all patients. Patient 1 re-
ceived HCT at age 8 and attained menarche at age
13 years. Patient 5 had primary amenorrhea at the
time of HCT at 18 years and continues to be amenor-
rheic. Five patients with stable engraftment and no
prior history of splenectomy were found to have
splenic regeneration on spleen scan (data not shown).
DISCUSSION
Since we first demonstrated ‘‘proof of principle’’
that an RIC conditioning regimen can lead to stable
donor erythropoiesis in a patient with severe SCD
a number of years ago [21], a number of studies of
transplantation for SCD have been published that
use conditioning regimens ranging from truly non-
myeloablative, to nearly myeloablative regimens [23].
In the current study, we demonstrate stable long-
term donor engraftment in 6 of 7 multiply transfused
patients with SCD following HCT from a matched
sibling donor using an RIC conditioning regimen.
This includes a multiply transfused young adult with
iron overload, ABO incompatibility and allo-sensitiza-
tion—all factors associated with increased risk of en-
graftment failure and delayed donor erythropoiesis
[24]. One of 7 patients rejected the graft because of
poor compliance with immunosuppressive medica-
tions. To date, this is the single largest study of
HCT following RIC conditioning for SCD where
consistent stable engraftment has been demonstrated
over a prolonged period of time.
Our results stand in distinct contrast to the high
rate of delayed loss of donor engraftment following
the withdrawal of immunosuppression, that has been
Figure 4. Lineage-specific peripheral blood donor chimerism at the
time of last contact (2-8.5 years post-HCT). Chimerism was examined
in the mononuclear (dark gray bars), CD31 lymphoid chimerism (light
gray), and red blood cell precursor (black bars) compartments.
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athies receiving HCT following minimal intensity
(\25% of the full myeloablative regimen) condition-
ing regimens [25,26]. These higher rates of delayed
graft loss in patients with SCD, relative to patients
with hematologic malignancies, may be related to di-
minished marrow space because of expanded erythro-
poiesis, a relatively robust intact immune system
unaltered by prior exposure to chemotherapy, and his-
tory of chronic transfusions leading to allo-sensitiza-
tion because of chronic transfusion and exposure to
alloantigens [27]. On the other hand, myeloablative
regimens or RIC conditioning regimens employing
near-myeloablative doses have been associated with
unacceptable regimen related toxicity in adults with
SCD [28]. Our regimen of BU/FLU/ATG/TLI using
busulfan at approximately 50% of the myeloablative
dose, together with FLU /TLI/ATG, our regimen
generates a high degree of immunosuppression in con-
junction with creation of marrow space, appears to be
able to strike a balance between dose intensity and de-
gree of associated toxicity. Conditioning with TLI/
ATG has been reported to markedly decrease the
incidence of aGVHD, possibly by enrichment of
host natural killer T cells [29-31] and can promote
engraftment of hematopoietic cells even in chemother-
apy naı¨ve subjects with intact hematopoietic and im-
mune systems [29,32]. Consistent with our findings,
various case reports have described successful donor
engraftment in patients with hemoglobinopathies
and nonmalignant disorders following HCT using
alternate conditioning regimens comprised of
chemotherapy at approximately 50% of the myeloa-
blative dose, together with immunosuppressive agents
[33-38].
Chimerism following a nonmyeloablative prepar-
ative regimen that is sufficient to establish stable long-
term donor-derived erythropoiesis and disease
amelioration in patients with SCD has long been
the subject of investigation [25,26]. Stable mixed chi-
merism has been reported to occur in 5% to 25% of
patients with SCD undergoing myeloablative HCT
[24]. In the nonmyeloablative setting, because recipi-
ent hematopoiesis is not fully ablated, mixed chime-
rism may occur even more frequently. Full donor T
cell engraftment has been reported to precede donor
myeloid engraftment, aGVHD, and disease regres-
sion in patients undergoing HCT following RIC con-
ditioning [39,40], and early achievement of 100%
donor T cell chimerism by day 30 has been consid-
ered necessary for full expression of the alloimmune
response [40]. However, we observed that stable do-
nor engraftment could be achieved even in the setting
of low levels of early lymphoid donor chimerism and
that lymphoid donor chimerism can slowly increase
over time. Further studies will be required to eluci-
date the mechanisms by which tolerance to donorcells is achieved in patients with SCD following
RIC conditioning.
Murine studies have demonstrated that 100% ery-
throid chimerism is essential for organ recovery fol-
lowing HCT for SCD [41]. We have previously
reported that donor-derived erythroid precursors are
relatively enriched in the face of mixed mononuclear
cell chimerism in patients with SCD because of
relative ineffective erythropoiesis of sickle-derived
erythroid precursors [19,42]. Consistent with our
previous studies, we observed total or near-complete
detection of donor-derived erythroid cells in periph-
eral blood in 6 of 7 patients over long-term follow-
up that was associated with clinical improvement.
We observed stable neurologic, pulmonary, and
cardiac status in our patient cohort following trans-
plantation. That 1 patient achieved menarche at nor-
mal age following HCT suggests that this
conditioning regimen may help preserve endocrine
ovarian function. Despite the escalated degree of
immunosuppression generated by our regimen, we
did not observe serious morbidity or mortality related
to bacterial or viral infections as has been reported in
some alemtuzumab-containing regimens [43,44].
Although the use of total lymphoid irradiation is a vari-
able risk factor for late treatment-related complica-
tions, such as malignancies [45-47], we have not
observed this complication. Persistence of lymphoid
cells of donor origin that have been exposed to radia-
tion may pose an as-yet unknown increased risk of
malignancies. A larger study with an even longer ob-
servation is necessary before the long-term risk of
TLI associated with this preparative regimen and in
this patient population can be determined.
GVHD is the other major cause of morbidity and
mortality in patients with hemoglobinopathies under-
going myeloablative HCT. We observed 1 patient
each with grade II aGVHD and limited cutaneous
cGVHD. This is not lower than the incidence of
GVHD observed in patients with SCD undergoing
myeloablative or RIC conditioning [7,10,28]. Con-
trary to early expectations, HCT following a nonmye-
loablative or RIC conditioning regimen for malignant
and nonmalignant disease has been associated with
a high incidence of GVHD [48]. For these reasons, it
is remarkable that we did not observe any severe
GVHD. Donor CD81 T cell count above the median
on day 114 after HCT may be associated with in-
creased risk of development of aGVHD grades II to
IV [49]. Further studies are indicated to determine if
the low incidence of severe GVHD in our patients is
related to the relatively low level of early donor lym-
phoid mixed chimerism.
The ability to reduce the dose of myelotoxic drugs
commonly used in conditioning regimen prior to
HCT has the potential to reduce the risk of early and
late regimen-related toxicity; decrease hospitalization
Biol Blood Marrow Transplant 14:1270-1278, 2008 1277Engraftment following HCT for Sickle Cell Diseaseand reduce the cost of the HCT procedure. Improved
tolerability of HCT may lead to this therapeutic op-
tion becoming available to older or high-risk patients,
those without sibling donors, or those with significant
morbidity but not meeting current criteria for HCT
[23,50]. Taken together, these data demonstrate en-
couraging results of using an immunosuppressive
RIC regimen, which create a balance between myelo-
suppression and immunoablation results in stable en-
graftment with minimal toxicity in patients with SCD.
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